0001104659-20-082854.txt : 20200710 0001104659-20-082854.hdr.sgml : 20200710 20200710202826 ACCESSION NUMBER: 0001104659-20-082854 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200710 DATE AS OF CHANGE: 20200710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Venture Capital VI, L.P. CENTRAL INDEX KEY: 0001687880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 201024146 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Ventures VI GP, L.P. CENTRAL INDEX KEY: 0001777654 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 201024147 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Ventures VI GP-GP, LLC CENTRAL INDEX KEY: 0001777652 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 201024148 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4/A 1 a4a.xml 4/A X0306 4/A 2020-01-02 2020-01-06 0 0001744659 Akero Therapeutics, Inc. AKRO 0001687880 Versant Venture Capital VI, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 0001777654 Versant Ventures VI GP, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 0001777652 Versant Ventures VI GP-GP, LLC ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 Common Stock 2020-01-02 4 S 0 10952 19.89 D 3645633 I See footnote Common Stock 2020-01-02 4 S 0 3900 21.2 D 3641733 I See footnote Common Stock 2020-01-02 4 S 0 1000 22.17 D 3640733 I See footnote Common Stock 2020-01-02 4 J 0 684143 0 D 2956590 I See footnote Common Stock 2020-01-02 4 J 0 13683 0 A 13683 I See footnote Common Stock 2020-01-02 4 J 0 13683 0 D 0 I See footnote Common Stock 2020-01-02 4 J 0 11803 0 A 11803 I See footnote Common Stock 2020-01-02 4 J 0 11803 0 D 0 I See footnote Common Stock 2020-01-03 4 S 0 3100 19.18 D 2953490 I See footnote Common Stock 2020-01-03 4 S 0 100 20.27 D 2953390 I See footnote Common Stock 2020-01-06 4 S 0 4968 17.68 D 2948422 I See footnote Common Stock 2020-01-06 4 S 0 6101 18.32 D 2942321 I See footnote Common Stock 2020-01-06 4 S 0 42323 19.93 D 2899998 I See footnote The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan. These sales were executed in multiple trades at prices ranging from $19.56 to $20.26. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $20.87 to $21.56. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $22.00 to $22.25. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital VI, L.P. ("Versant VI") without consideration to its partners. Represents a change in the form of ownership of Versant Ventures VI GP, LP ("Versant GP LP") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant VI. The shares are held by Versant GP LP. Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and may be deemed to have voting and investment power over the securities held by Versant GP LP and as a result may be deemed to have beneficial ownership over such securities. Versant GP LLC disclaims beneficial ownership over these securities except to the extent of its pecuniary interest therein. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LP without consideration to its partners. Represents a change in the form of ownership of Versant GP LLC by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant GP LP. The shares are held by Versant GP LLC. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LLC without consideration to its members. These sales were executed in multiple trades at prices ranging from $19.00 to $19.48. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $20.25 to $20.32. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $17.00 to $17.98. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $18.00 to $18.99. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $19.55 to $20.22. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These shares are owned directly by Versant VI. Versant GP LP is the general partner of Versant VI and Versant GP LLC is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein. This Form 4/A to the Form 4 filed with the Securities and Exchange Commission on January 6, 2020 is being amended and restated in its entirety to correct the aggregate number of securities beneficially owned by Versant VI in Table I, Column 5. All other information reported in the original Form 4 remains unchanged. VERSANT VENTURE CAPITAL VI, L.P. By: Versant Ventures VI GP, L.P., its general partner By: Versant Ventures VI GP-GP, LLC, its general partner By: /s/ Robin L. Praeger, Managing Director 2020-07-10 VERSANT VENTURES VI GP, L.P. By: Versant Ventures VI GP-GP, LLC, its general partner Its: General Partner By: /s/ Robin L. Praeger, Managing Director 2020-07-10 VERSANT VENTURES VI GP-GP, LLC By: /s/ Robin L. Praeger, Managing Director 2020-07-10